Seedlabs

DSI Trace: Automated Provenance Reports for Biodata Benefit-Sharing

A compliance tool that automatically documents which versioned biodata resources (each now DOI-identified) a company's pipelines and publications used, generating the usage disclosures required under digital sequence information benefit-sharing rules.

Biochemistry, Genetics and Molecular BiologyGenomics and Phylogenetic Studies
AI Governance and Cognitive ImpactBiotech R&D compliance: automated digital sequence information (DSI) provenance and benefit-sharing disclosure.

Concept

A compliance product that reconstructs which versioned biodata resources an organization's research and product development actually relied on. It reads pipeline configurations (e.g., which SILVA release's QIIME2/DADA2/KRAKEN2 classifier was invoked), data-management plans, and methods sections, and emits a standardized, machine-readable usage disclosure for digital sequence information (DSI) mapped to access-and-benefit-sharing obligations. The single wedge: turn DSI provenance from a manual legal review into an automated, auditable report.

Why now

SILVA has begun assigning DOIs to every release, making database usage precisely citable and traceable — the technical prerequisite for automated DSI accounting. Its integration into the DSMZ Digital Diversity consortium alongside LPSN and StrainInfo standardizes identifiers across the major microbial biodata resources, so cross-database provenance is feasible rather than a research project. The governance need is documented: digital sequence information falls under the Convention on Biological Diversity's access-and-benefit-sharing framework, with active development of mechanisms to track and reward DSI use — mechanisms that only function at scale if usage can be reported automatically.

Written by GLM · 13 Oct 2026

AI assessment

Backed by 2 papers89

A high-utility compliance tool that leverages new DOI standards in biodata to automate a mandatory and currently painful legal requirement for biotech companies.

Evidence strength
5/5
The idea directly connects the technical implementation of DOIs in SILVA/DSMZ (Paper 1) with the documented legal and administrative burden of DSI/ABS compliance (Paper 2).
Market pull
4/5
Biotech firms (Ginkgo, Novonesis) face significant regulatory risk and administrative overhead regarding the Nagoya Protocol, creating a strong pull for automation.
Novelty & moat
4/5
While other provenance tools exist for AI or charts, this is a domain-specific application for biodata compliance that fills a distinct regulatory gap.
Feasibility
4/5
The MVP is a parser for pipeline configs and methods sections mapped to a DOI database, which is technically straightforward given the new SILVA standards.
Wedge clarity
5/5
The wedge is extremely sharp: transforming manual DSI legal review into an automated, auditable report.
Simplicity / focus
5/5
The product is focused on a single, clear output (the provenance report) rather than attempting to build a broad data management platform.

Scored by Gemma 4 · 13 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Leibniz Institute DSMZorganization

    As host of the DSMZ Digital Diversity consortium behind SILVA, LPSN, and StrainInfo, it could use automated usage reports to demonstrate impact and justify the long-term sustainability of its core biodata resources to funders.

  • Novonesiscompany

    The Danish biosolutions company commercializes products built on microbial sequence data; automated DSI usage disclosure reduces the compliance burden as benefit-sharing mechanisms around digital sequence information take effect.

  • Ginkgo Bioworkscompany

    The synthetic biology company draws heavily on public sequence databases in commercial organism design and needs auditable records of which versioned resources its pipelines used.

  • Secretariat of the Convention on Biological Diversityorganization

    The body operating the DSI benefit-sharing mechanism needs standardized, machine-readable usage disclosures from industry; automated provenance reporting makes any such mechanism workable at scale.

Research it builds on

  1. SILVA in 2026: a global core biodata resource for rRNA within the DSMZ digital diversity
    Maria S. Chuvochina, Jan Gerken, Martinique Frentrup et al. · 2025 · 106 citations
    All ideas from this paper →
  2. The Case for Community Self-Governance on Access and Benefit Sharing of Digital Sequence Information
    Rebecca A Adler Miserendino, Rachel Sarah Meyer, Breda M. Zimkus et al. · 2022 · 7 citations
    All ideas from this paper →
Leave feedback
feasibility